IL6 and rheumatoid arthritis: The potential of S1P3 as a therapeutic target for RA was evaluated in a CIA model using S1pr3-deficient mice, where these mice exhibited significantly lower clinical and histological scores, as well as reduced synovial IL-6 expression, compared to WT mice [19].